Iatrogenic QT Prolongation

Comprehensive Toxicology, Second Edition

Volumn 6, Issue , 2010, Pages 365-402

  Bialecki, R A ^a   Lainee, P ^a   Valentin, J P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Adverse drug reaction; Cardiac action potential; Cardiac arrhythmia; Cardiac electrophysiology; Cardiac ion channels; Electrocardiography; HERG; Human ether go go K+ channel (Kv11.1); Long QT syndrome; Preclinical drug evaluation; QT interval prolongation; QT shortening; Risk assessment; Sudden cardiac death; Torsade de pointes; Ventricular repolarization

Indexed keywords

EID: 85012857753     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-046884-6.00718-1     Document Type: Chapter

References (216)

1. Abbott G., Sesti F., Splawski I., Buck M., Lehmann M., Timothy K., Keating M., Goldstein S. Cell 2008, 97:175-187.
2. Abi-Gerges N., Small B.G., Lawrence C.L., Hammond T.G., Valentin J.P., Pollard C.E. Br. J. Clin. Pharmacol. 2004, 142(8):1255-1264.
3. Abriel H., Schlapfer J., Keller D.I., Gavillet B., Buclin T., Biollaz J., Stoller R., Kappenberger L. Swiss Med. Wkly. 2004, 134(47-48):685-694.
4. Ahnve S. Am. Heart J. 1985, 109:568-574.
5. Akita M., Shibazaki Y.I.M., Hiratsuka K., Sakai T., Kurosawa T. J. Toxicol. Sci. 2004, 29:63-71.
6. Al-Khatib S.M., LaPointe N.M., Kramer J.M., Califf R.M. J. Am. Med. Assoc. 2003, 289(16):2120-2127. [erratum appears in JAMA 2003, 290(10), 1318, September 10].
7. Anantharam A., Abbott G. Novartis Foundation Symposium, The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome 2005, Vol. 266:100-112. John Wiley & Sons Ltd., Chichester. D.J. Chadwick, J. Goode (Eds.).
8. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., Sakamoto K., Kitani S., Yamamoto Y., Hizume S., et al. J. Pharmacol. Sci. 2005, 99(5):487-500.
9. Angelo K., Korolkova Y.V., Grunnet M., Grishin E.V., Pluzhnikov K.A., Klaerke D.A., Knaus H.G., Moller M., Olesen S.P. Pflugers Arch. 2003, 447(1):55-63.
10. Anon, Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, Committee for Proprietary Medicinal Products, London, CPMP/986/96, 1997.
11. Anon, Guidance for Industry: S7A Safety Pharmacology Studies for Human Pharmaceuticals, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2001.
12. Anon, The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT interval Prolongation) by Human Pharmaceuticals S7B, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2005a.
13. Anon, E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2005b.
14. Anon, Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies, Center for Drug Evaluation and Research, Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2006.
15. Antzelevitch C. Eur. J. Clin. Invest. 2001, 31(7):555-557.
16. Antzelevitch C., Belardinelli L., Wu L., Fraser H., Zygmunt A.C., Burashnikov A., Diego J.M., Fish J.M., Cordeiro J.M., Goodrow R.J., et al. J. Cardiovasc. Pharmacol. Ther. 2004, 9(Suppl. 1):S65-S83.
17. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., Cordeiro J.M., Thomas G. Circulation 2004, 110(8):904-910.
18. Antzelevitch C., Fish J. Basic Res. Cardiol. 2001, 96(6):517-527.
19. Antzelevitch C., Shimizu W. Curr. Opin. Cardiol. 2001, 17(1):43-51.
20. Antzelevitch C., Shimizu W., Yan G.X., Sicouri S., Weissenburger J., Nesterenko V.V., Burashnikov A., Di D.J., Saffitz J., Thomas G.P. J. Cardiovasc. Electrophysiol. 1999, 10(8):1124-1152.
21. Antzelevitch C., Sicouri S., Litovsky S.H., Lukas A., Krishnan S.C., Di Diego J.M., Gintant G.A., Liu D.W. Circ. Res. 1991, 69(6):1427-1449.
22. Antzelevitch C., Sun Z.Q., Zhang Z.Q., Yan G.X. J. Am. Coll. Cardiol. 1996, 28(7):1836-1848.
23. Banach K., Halbach M.D., Hu P., Hescheler J., Egert U. Am. J. Physiol. Heart Circ. Physiol. 2003, 284(6):H2114-H2123.
24. Baranowska M., Kozlowska H., Korbut A., Malinowska B. Postepy Higieny i Medycyny do Swiadczalnej 2007, 61:596-605.
25. Bardy G.H., Ungerleider R.M., Smith W.M., Ideker R.E. Circulation 1983, 67(1):52-59.
26. Batchvarov V., Hnatkova K., Camm A.J., Malik M. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H2356-H2363.
27. Batey A.J., Doe C.P.A. J. Pharmacol. Toxicol. Methods 2002, 48(1):11-19.
28. Beatch G.N. Br. J. Clin. Pharmacol. 1996, 119:120P.
29. Belardinelli L., Antzelevitch C., Vos M.A. Trends Pharmacol. Sci. 2003, 24(12):619-625.
30. Betat, A. M.; Louis, E.; Froget, G. L. P.; Forster, R. Influence of hypokalemia on drug-induced QT prolongation in the conscious telemetered guinea pig. 4th Annual Meeting of the Safety Pharmacology Society, Covington, USA, 2004 [Abstract].
31. Bjerregaard P., Gussak I. Ann. Noninvasive Electrocardiol. 2005, 10(4):436-440.
32. Borchert B., Lawrenz T., Stellbrink C. Herzschrittmacherther. Elektrophysiol. 2006, 17(4):205-210.
33. Brachmann J., Scherlag B.J., Rosenshtraukh L.V., Lazzara R. Circulation 1983, 68(4):846-856.
34. Bridgland-Taylor M.H., Hargreaves A.C., Easter A., Orme A., Henthorn D.C., Ding M., Davis A.M., Small B.G., Heapy C.G., Abi-Gerges N., et al. J. Pharmacol. Toxicol. Methods 2006, 54(2):189-199.
35. Brooks R.R., Drexler A.P., Maynard A.E., Al-Khalidi H., Kostreva D.R. Exp. Biol. Med. 2000, 223:183-189.
36. Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., Annest J.L. J. Am. Med. Assoc. 2006, 296(15):1858-1866.
37. Burashnikov A., Antzelevitch C. J. Cardiovasc. Electrophysiol. 1998, 9:934-938.
38. Carlsson L., Abrahamsson C., Andersson B., Duker G., Schiller-Linhardt G. Cardiovasc. Res. 1993, 27:2186-2193.
39. Carlsson L., Almgren O., Duker G. J. Cardiovasc. Pharmacol. 1990, 16:276-285.
40. Cavero I. Expert Opin. Drug Saf. 2008, 7(1):91-100.
41. Cerrone M., Noujaim S., Jalife J. J. Intern. Med. 2006, 259(1):24-38.
42. Chezalviel-Guilbert F., Deplanne V., Davy J.M., Poirier J.M., Xia Y.Z., Cheymol G., Weissenburger J. J. Cardiovasc. Electrophysiol. 1998, 9(5):498-507.
43. Chezalviel-Guilbert F., Weissenburger J., Davy J.M., Guhennec C., Poirier J.M., Cheymol G. Fundam. Clin. Pharmacol. 1995, 9(3):240-247.
44. Chiba K., Sugiyama A., Satoh Y., Shiina H., Hashimoto K. Toxicol. App. Pharmacol. 2000, 169:8-16.
45. Chiba K., Sugiyama A., Takasuna K., Hashimoto K. Eur. J. Clin. Pharmacol. 2004, 502(1-2):117-122.
46. Chiu P.J., Marcoe K.F., Bounds S.E., Lin C.H., Feng J.J., Lin A., Cheng F.C., Crumb W.J., Mitchell R. J. Pharmacol. Sci. 2004, 95(3):311-319.
47. Cordes J.S., Sun Z., Lloyd D.B., Bradley J.A., Opsahl A.C., Tengowski M.W., Chen X., Zhou J. Br. J. Pharmacol. 2005, 145(1):15-23.
48. Curtis L.H., Ostbye T., Sendersky V., Hutchison S., Allen LaPointe N.M., Al-Khatib S.M., Usdin Y.S., Dans P.E., Wright A., Califf R.M., et al. Am. J. Med. 2003, 114(2):135-141.
49. Davie C., Valentin J.P., Pollard C., Standen N., Mitcheson J., Alexander P., Thong B. J. Cardiovasc. Electrophysiol. 2004, 15(11):1302-1309.
50. Davila J.C., Cezar G.G., Thiede M., Strom S., Miki T., Trosko J. Toxicol. Sci. 2004, 79(2):214-223.
51. Davy J.M., Sirinelli A., Le G.D., Sebag C., Motte G. Eur. Heart J. 1988, 9(Suppl. B):5-12.
52. Davy J.M., Weissenburger J., Chezalviel F., Poirier J.M., Lainee P., Ertzbischoff O., Cheymol G., Motte G. J. Electrophysiol. 1989, 3(5):339-345.
53. Davy J.M., Weissenburger J., Ertzbischoff O., Lainee P., Chezalviel F., Poirier J.M., Cheymol G., Motte G. Arch. Mal. Coeur Vaiss. 1988, 81(9):1117-1124.
54. De Bruin M.L., Pettersson M., Meyboom R.H., Hoes A.W., Leufkens H.G. Eur. Heart J. 2005, 26(6):590-597.
55. De Ponti F., Poluzzi E., Montanaro N., Ferguson J. Lancet 2000, 356(9223):75-76.
56. Dennis A., Wang L., Wan X., Ficker E. Biochem. Soc. Trans. 2007, 35(Pt. 5):1060-1063.
57. Dessertenne F. Arch. Mal. Coeur Vaiss. 1966, 59(2):263-272.
58. Di Diego J.M., Belardinelli L., Antzelevitch C. Circulation 2003, 108(8):1027-1033.
59. Dixit R. Am. Pharm. Outsourcing 2004, 5(2):30-37.
60. Dorn A., Hermann F., Ebneth A., Bothmann H., Trube G., Christensen K., Apfel C. J. Biomol. Screen. 2005, 10(4):339-347.
61. Drvota V., Blange I., Häggblad J., Sylven C. J. Cardiovasc. Pharmacol. 1998, 32:645-661.
62. Duker G., Almgren O., Axenborg J. Pharmacol. Toxicol. 1988, 63(2):85-89.
63. Eckardt L., Meissner A., Kirchhof P., Weber T., Milberg P., Breithardt G., Haverkamp W. Methods 2003, 30(2):109-114.
64. Eckhardt L.L., Rajamani S., January C.T. Br. J. Pharmacol. 2005, 145(1):3-4.
65. Egan W.J., Zlokarnik G., Grootenhuis P.D.J. Drug Discov. Today: Technol. 2004, 1(4):381-387.
66. Ehrlich J., Pourrier M., Weerapura M. J. Biol. Chem. 2004, 279:1233-1241.
67. el-Sherif N., Zeiler R.H., Craelius W., Gough W.B., Henkin R. Circ. Res. 1988, 63(2):286-305.
68. Feld Y., Melamed-Frank M., Kehat I., Tal D., Marom S., Gepstein L. Circulation 2002, 105(4):522-529.
69. Fermini B., Fossa A.A. Nat. Rev. Drug Discov. 2003, 2(6):439-447.
70. Ficker E., Kuryshev Y.A., Dennis A.T., Obejero-Paz C., Wang L., Hawryluk P., Wible B.A., Brown A.M. Mol. Pharmacol. 2004, 66(1):33-44.
71. Finlayson K., Witchel H.J., McCulloch J., Sharkey J. Eur. J. Clin. Pharmacol. 2004, 500(1-3):129-142.
72. Fitch R.W., Daly J.W. Anal. Biochem. 2005, 342(2):260-270.
73. Fossa A.A., DePasquale M.J., Raunig D.L., Avery M.J., Leishman D.J. J. Pharmacol. Exp. Ther. 2002, 302(2):828-833.
74. Fossa A.A., Wisialowski T., Crimin K. J. Pharmacol. Exp. Ther. 2006, 316(2):498-506.
75. Fossa A.A., Wisialowski T., Magnano A., Wolfgang E., Winslow R., Gorczyca W., Crimin K., Raunig D.L. J. Pharmacol. Exp. Ther. 2005, 312(1):1-11.
76. Friedrichs G.S., Patmore L., Bass A. J. Pharmacol. Toxicol. Methods 2005, 52(1):6-11.
77. Fung M., Thornton A., Mybeck K., Wu J., Hornbuckle K., Muniz E. Drug Info. J. 2001, 35:293-317.
78. Gauvin D.V., Tilley L.P., Smith F.W., Baird T.J. J. Pharmacol. Toxicol. Methods 2006, 53(2):140-151.
79. Gauvin D.V., Tilley L.P., Smith F.W., Baird T.J. J. Pharmacol. Toxicol. Methods 2006, 53(2):128-139.
80. Gavaghan C.L., Arnby C.H., Blomberg N., Strandlund G., Boyer S. J. Comput. Aided Mol. Des. 2007, 21(4):189-206.
81. Gill S., Gill R., Lee S.S., Hesketh J.C., Fedida D., Rezazadeh S., Stankovich L., Liang D. Assay Drug Dev. Technol. 2003, 1(5):709-717.
82. Grisanti S., Morganroth J., Shah R. Appl. Clin. Trials 2005, (Suppl.). http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Labs+Articles/A-Practical-Approach-to-Cardiac-Safety/ArticleStandard/Article/detail/182765.
83. Guldner N.W., Kajahn J., Klinger M., Sievers H.H., Kruse C. Int. J. Artif. Organs 2006, 29(12):1158-1166.
84. Guo L., Guthrie H. J. Pharmacol. Toxicol. Methods 2005, 52(1):123-135.
85. Gussak I., Brugada P., Brugada J., Wright R.S., Kopecky S.L., Chaitman B.R., Bjerregaard P. Cardiology 2000, 94(2):99-102.
86. Guthrie H., Livingston F.S., Gubler U., Garippa R. J. Biomol. Screen. 2005, 10(8):832-840.
87. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Pflugers Arch. 1981, 391(2):85-100.
88. Hammond T.G., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Redfern W.S., Sullivan A.T., Camm A.J. Cardiovasc. Res. 2001, 49(4):741-750.
89. Harmer A., Abi-Gerges N., Easter A., Woods A., Lawrence C., Small B., Valentin J., Pollard C. J. Pharmacol. Toxicol. Methods 2008, 57(1):30-41.
90. Hoffmann P., Warner B. J. Pharmacol. Toxicol. Methods 2006, 53(2):87-105.
91. Holbrook M., Malik M., Shah R.R., Valentin J.P. J. Pharmacol. Toxicol. Methods 2008, 59(1):21-28.
92. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., Burkett D.E., Durham S.K. J. Pharmacol. Toxicol. Methods 2007, 55(2):159-175.
93. Hondeghem L.M. J. Cardiovasc. Electrophysiol. 1994, 5(8):711-721.
94. Hondeghem L.M., Carlsson L., Duker G. Circulation 2001, 103(15):2004-2013.
95. Hondeghem L.M. J. Cardiovasc. Electrophysiol. 2006, 17(3):337-340.
96. Horii I., Kito G., Hamada T., Jikuzono T., Kobayashi K., Hashimoto K. J. Toxicol. Sci. 2002, 27(2):123-130.
97. Igarashi T., Nakane S., Kitagawa T. J. Toxicol. Sci. 1995, 20(2):77-92.
98. Joshi A., Dimino T., Vohra Y., Cui C., Yan G.X. J. Electrocardiol. 2004, 37(Suppl.):7-14.
99. Kano M., Toyoshi T., Iwasaki S., Kato M., Shimizu M., Ota T. J. Pharmacol. Sci. 2005, 99(5):501-511.
100. Kay G.N., Plumb V.J., Arciniegas J.G., Henthorn R.W., Waldo A.L. J. Am. Coll. Cardiol. 1983, 2(5):806-817.
101. Kehat I., Gepstein A., Spira A., Itskovitz-Eldor J., Gepstein L. Circ. Res. 2002, 91(8):659-661.
102. Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., Livne E., Binah O., Itskovitz-Eldor J., Gepstein L. J. Clin. Invest. 2001, 108(3):407-414.
103. Kennedy T. Drug Discov. Today 1997, 2(10):436-444.
104. Korolkova Y.V., Bocharov E.V., Angelo K., Maslennikov I.V., Grinenko O.V., Lipkin A.V., Nosyreva E.D., Pluzhnikov K.A., Olesen S.P., Arseniev A.S., et al. J. Biol. Chem. 2002, 277(45):43104-43109.
105. Kupershmidt S., Yang I.C., Hayashi K., Wei J., Chanthaphaychith S., Petersen C.I., Johns D.C., George A.L., Roden D.M., Balser J.R. FASEB J. 2003, 17(15):2263-2265.
106. Kurtz T.W., Griffin K.A., Bidani A.K., Davisson R.L., Hall J.E. Arterioscler. Thromb. 2005, 25(3):e22-e33.
107. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., Brown A.M., Kang J., Chen X.L., Sawamura K., et al. J. Pharmacol. Exp. Ther. 2005, 312(1):316-323.
108. Lainée P., Perez L., Dubreuil B., Gillet G. Jpn. Pharmacol. Ther. 1998, 26(Suppl. 4):251-261.
109. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., Bor D.H. JAMA 2002, 287(17):2215-2220.
110. Lau C.P., Freedman A.R., Fleming S., Malik M., Camm A.J., Ward D.E. Cardiovasc. Res. 1988, 22:67-72.
111. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. J. Pharmacol. Toxicol. Methods 2005, 52(1):46-59.
112. Leeson P.D., Springthorpe B. Nat. Rev. Drug Discov. 2007, 6(11):881-890.
113. Liu B.A., Juurlink D.N. N. Engl. J. Med. 2004, 351(11):1053-1056.
114. Lu H.R., Remeysen P., De Clerck F. J. Cardiovasc. Pharmacol. 2000, 36:728-736.
115. Malik M. J. Cardiovasc. Electrophysiol. 2001, 12(4):411-420.
116. Malik M., Hnatkova K., Batchvarov V. Pacing Clin. Electrophysiol. 2004, 27(6):791-800.
117. Männikkö R., Valentin J.-P., Pollard C.E. Providing evidence for inhibition of hERG trafficking using IonWorksHT™. Biophysical Society Meeting. Biophys. J. 2006, 90(Suppl. 5N). [Abstract 1973-Pos].
118. Matsunaga T., Mitsui T., Harada T., Inokuma M., Murano H., Shibutani Y. J. Pharmacol. Toxicol. Methods 1997, 38(4):201-209.
119. McDonald T., Yu Z., Ming Z., Palma E., Meyers M.B., Wang K.W., Goldstein S.A., Fishman G.I. Nature 1997, 388:289-292.
120. Meyer T., Boven K.H., Gunther E., Fejtl M. Drug Safety 2004, 27(11):763-772.
121. Milan D.J., Jones I.L., Ellinor P.T., MacRae C.A. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(1):H269-H273.
122. Milan D.J., Peterson T.A., Ruskin J.N., Peterson R.T., MacRae C.A. Circulation 2003, 107(10):1355-1358.
123. Mills P.A., Huetteman D.A., Brockway B.P., Zwiers L.M., Gelsema A.J., Schwartz R.S., Kramer K. J. Appl. Physiol. 2000, 88(5):1537-1544.
124. Milnes J.T., Dempsey C.E., Ridley J.M., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. FEBS Lett. 2003, 547(1-3):20-26.
125. Mitcheson J., Perry M., Stansfeld P., Sanguinetti M.C., Witchel H., Hancox J. Novartis Found. Symp. 2005, 266:136-158.
126. Mitcheson J.S., Chen J., Sanguinetti M.C. J. Gen. Physiol. 2000, 115(3):229-240.
127. Mitcheson J.S., Perry M.D. Curr. Opin. Drug Discov. Devel. 2003, 6(5):667-674.
128. Miyazaki H., Watanabe H., Kitayama T., Nishida M., Nishi Y., Sekiya K., Suganami H., Yamamoto K. J. Pharmacol. Sci. 2005, 99(5):523-529.
129. Moss A. Am. J. Cardiol. 1993, 72:23B-25B.
130. Motte G., Coumel P., Abitbol G., Dessertenne F., Slama R. Arch. Mal. Coeur Vaiss. 1970, 63(6):831-853.
131. Murphy S.M., Palmer M., Poole M.F., Padegimas L., Hunady K., Danzig J., Gill S., Gill R., Ting A., Sherf B., et al. J. Pharmacol. Toxicol. Methods 2006, 54(1):42-55.
132. Nahas K., Geffray B. J. Pharmacol. Toxicol. Methods 2004, 50(3):201-207.
133. Netzer R., Bischoff U., Ebneth A. Curr. Opin. Drug Discov. Devel. 2003, 6(4):462-469.
134. Noble D. Science 2002, 295(5560):1678-1682.
135. Noble D. Physiology 2004, 19:191-197.
136. Offenhausser A., Knoll W. Trends Biotechnol. 2001, 2:62-66.
137. Olivier N.B., Eyster G.E., Sanders R., Cheng J., Bohart G., Girand M., Bailie M. J. Cardiovasc. Electrophysiol. 2003, 14(12):1356-1360.
138. Olsen K.M. J. Fam. Pract. 2005, (Suppl.):S8-S14.
139. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., et al. Regul. Toxicol. Pharmacol. 2000, 32(1):56-67.
140. Omata T., Kasai C., Hashimoto M., Hombo T., Yamamoto K. J. Pharmacol. Sci. 2005, 99(5):531-541.
141. Pardo-Lopez L., Zhang M., Liu J., Jiang M., Possani L.D., Tseng G.N. J. Biol. Chem. 2002, 277(19):16403-16411.
142. Parihar A.S., Groebe D.R., Scott V.E., Feng J., Zhang X.F., Warrior U., Gopalakrishnan M., Shieh C.C. Assay Drug Dev. Technol. 2003, 1(5):647-654.
143. Parng C. Curr. Opin. Drug Discov. Devel. 2005, 8(1):100-106.
144. Passier R., Denning C., Mummery C. Handb. Exp. Pharmacol. 2006, 174:101-122.
145. Priest B.T., Swensen A.M., McManus O.B. Curr. Pharm. Des. 2007, 13(23):2325-2337.
146. Provan G., Stanton A., Sutton A., RankinBurkart A., Laycock S.K. J. Pharmacol. Toxicol. Methods 2005, 52(2):223-228.
147. Rampe D., Roy M.L., Dennis A., Brown A.M. FEBS Lett. 1997, 417(1):28-32.
148. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., et al. Cardiovasc. Res. 2003, 58(1):32-45.
149. Redfern W.S., Wakefield I.D., Prior H., Pollard C.E., Hammond T.G., Valentin J.P. Fundam. Clin. Pharmacol. 2002, 16(3):161-173.
150. Redfern W.S., Waldron G., Winter M., Butler P., Holbrook M., Wallis R., Valentin J.P. J. Pharmacol. Toxicol. Methods 2008, 58(2):110-117.
151. Rezazadeh S., Hesketh J.C., Fedida D. J. Biomol. Screen. 2004, 9(7):588-597.
152. Robertson G.A., January C.T. Handb. Exp. Pharmacol. 2006, 171:349-355.
153. Roden D.M., Hoffman B.F. Circ. Res. 1985, 56(6):857-867.
154. Roden D.M., George A.L. Annu. Rev. Med. 1996, 47:135-148.
155. Rubinstein A.L. Curr. Opin. Drug Discov. Devel. 2003, 6(2):218-223.
156. Sakaguchi Y., Sugiyama A., Takao S., Akie Y., Takahara A., Hashimoto K. J. Pharmacol. Sci. 2005, 99(2):185-190.
157. Sanguinetti M.C., Tristani-Firouzi M. Nature 2006, 440(7083):463-469.
158. Sarapa N. Am. Pharm. Outsourcing 2003, 4(5):42-46.
159. Sasaki H., Shimizu N., Suganami H., Yamamoto K. J. Pharmacol. Sci. 2005, 99(5):513-522.
160. Schneider J., Hauser R., Andreas J.O., Linz K., Jahnel U. Eur. J. Clin. Pharmacol. 2005, 512(1):53-60.
161. Selzer A., Wray H. Circulation 1964, 30:17-26.
162. Sesti F., Abbott G.W., Wei J., Murray K.T., Saksena S., Schwartz P.J., Priori S.G., Roden D.M., George A.L., Goldstein S.A. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(19):10613-10618.
163. Shah R.R., Hondeghem L.M. Heart Rhythm 2005, 2(7):758-772.
164. Shiotani M., Harada T., Abe J., Sawada Y., Hashimoto K., Hamada Y., Horii I. J. Toxicol. Sci. 2005, 30(3):239-247.
165. Spitsbergen J.M., Kent M.L. Toxicol. Pathol. 2003, 31(Suppl.):62-87.
166. Stenger D.A., Gross G.W., Keefer E.W., Shaffer K.M., Andreadis J.D., Ma W., Pancrazio J.J. Trends Biotechnol. 2001, 8:304-309.
167. Stephens M. Stephens' Detection of New Adverse Drug Reactions 2004, John Wiley and Sons, Chichester, England. 5th ed.
168. Stett A., Egert U., Guenther E., Hofmann F., Meyer T., Nisch W., Haemmerle H. Anal. Bioanal. Chem. 2003, 377(3):486-495.
169. Sugiyam A., Ishida Y., Satoh Y., Aoki S., Hori M., Akie Y., Kobayashi Y., Hashimoto K. Jpn. J. Pharmacol. 2002, 88(3):341-350.
170. Sun Z.Q., Eddlestone G.T., Antzelevitch C. Pace 1997, 20(Pt. II):1116.
171. Surawicz B. J. Am. Coll. Cardiol. 1989, 14(1):172-184.
172. Szabó G., Szentandrássy N., Bíró T., Tóth B.I., Czifra G., Magyar J., Bányász T., Varró A., Kovács L., Nánási P. Pflugers Arch. 2005, 450(5):307-316.
173. Takahara A., Sugiyama A., Satoh Y., Wang K., Honsho S., Hashimoto K. Eur. J. Clin. Pharmacol. 2005, 507(1-3):169-177.
174. Tang W., Kang J., Wu X., Rampe D., Wang L., Shen H., Li Z., Dunnington D., Garyantes T. J. Biomol. Screen. 2001, 6(5):325-331.
175. Tattersall M.L., Dymond M., Hammond T., Valentin J.P. J. Pharmacol. Toxicol. Methods 2006, 53(1):11-19.
176. ten Tusscher K.H., Noble D., Noble P.J., Panfilov A.V. Am. J. Physiol. Heart Circ. Physiol. 2004, 286(4):H1573-H1589.
177. Thai K.M., Ecker G.F. Curr. Med. Chem. 2007, 14(28):3003-3026.
178. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., van Opstal J., Volders P.G., Vos M.A. Circulation 2004, 110(16):2453-2459.
179. Thomsen M.B., Volders P.G., Stengl M., Spatjens R.L., Beekman J.D., Bischoff U., Kall M.A., Frederiksen K., Matz J., Vos M.A. J. Pharmacol. Exp. Ther. 2003, 307(2):776-784.
180. Thomsen M.B., Matz J., Volders P.G.A., Vos M.A. Pharmacol. Ther. 2006, 112(1):150-170.
181. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., Moore N. Toxicol. Appl. Pharmacol. 2004, 199(1):52-60.
182. Tseng G.N. J. Mol. Cell Cardiol. 2001, 33(5):835-849.
183. Tseng G.N., Sonawane K.D., Korolkova Y.V., Zhang M., Liu J., Grishin E.V., Guy H.R. Biophys. J. 2007, 92(10):3524-3540.
184. Valentin J.P., Hammond T. J. Pharmacol. Toxicol. Methods 2008, 58(2):77-87.
185. van der Linde H., Van de Water A., Loots W., Van Deuren B., Lu H.R., Van Ammel K., Peeters M., Gallacher D.J. J. Pharmacol. Toxicol. Methods 2005, 52(1):168-177.
186. Vandenberg J.I., Walker B.D., Campbell T.J. Trends Pharmacol. Sci. 2001, 22(5):240-246.
187. Vargas H., Bass A., Breidenbach A., Feldman H., Gintant G., Harmer A., Heath B., Hoffmann P., Lagrutta A., Leishmann D., et al. J. Pharmacol. Toxicol. Methods 2008, 58(2):72-76.
188. Verduyn S.C., van Opstal J.M., Leunissen J.D., Vos M.A. J. Cardiovasc. Pharmacol. Ther. 2001, 6(1):89-97.
189. Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. J. Pharmacol. Exp. Ther. 2002, 302(1):320-327.
190. Volders P.G.A., Vos M.A., Szabo B., Sipido K.R., De Groot S.H.M., Gorgels A.P.M., Wellens H.J.J., Lazzara R. Cardiovasc. Res. 2008, 46(3):376-392.
191. Vos M.A., Verduyn S.C., Gporgels A.P., Lipcsei G.C., Wellens H.J. Circulation 1995, 92(6):1666-1667.
192. Wallis, R. QT - Understanding the complexities of defining the translation of animal data to humans. Seventh Annual Meeting of the Safety Pharmacology Society, Edinburgh, 2007.
193. Wanke E., Restano-Cassulini R. Toxicon. 2007, 49(2):239-248.
194. Watanabe H., Miyazaki H. J. Pharmacol. Toxicol. Methods 2006, 53(3):234-241.
195. Webster R., Leishman D., Walker D. Curr. Opin. Drug Discov. Devel. 2002, 5(1):116-126.
196. Weerapura M., Nattel S., Chartier D., Caballero R., Hebert T.E. J. Physiol. 2002, 540(Pt. 1):15-27.
197. Weissenberger J., Davy J.M., Chezalviel F., Ertzbischoff O., Poirier J.M., Engel F., Lainee P., Penin E., Motte G., Cheymol G. J. Pharmacol. Exp. Ther. 1991, 259(2):871-883.
198. Weissenburger J., Davy J.M., Chezalviel F. Fundam. Clin. Pharmacol. 1993, 7:29-38.
199. Weissenburger J., Nesterenko V.V., Antzelevitch C. Pace 1996, 19(Pt. II):707.
200. Weissenburger J., Noyer M., Cheymol G., Jaillon P. Clin. Exp Allergy 1999, 29(Suppl. 3):190-196.
201. Whelton P.K., Watson A.J. Am. J. Cardiol. 1986, 58(2):5A-10A.
202. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., Brown A.M. J. Pharmacol. Toxicol. Methods 2005, 52(1):136-145.
203. Wisialowski T., Crimin K., Engtrakul J., O'Donnell J., Fermini B., Fossa A.A. J. Pharmacol. Exp. Ther. 2006, 318(1):352-359.
204. Witchel H.J., Dempsey C.E., Sessions R.B., Perry M., Milnes J.T., Hancox J.C., Mitcheson J.S. Mol. Pharmacol. 2004, 66(5):1201-1212.
205. Witchel H.J., Milnes J.T., Mitcheson J.S., Hancox J.C. J. Pharmacol. Toxicol. Methods 2002, 48(2):65-80.
206. Wood C., Williams C., Waldron G.J. Drug Discov. Today 2004, 9(10):434-441.
207. Yan G.X., Antzelevitch C. Circulation 1998, 98:1928-1936.
208. Yan G.X., Wu Y., Liu T., Wang J., Marinchak R.A., Kowey P.R. Circulation 2001, 103(23):2851-2856.
209. Yang T., Roden D.M. Circulation 1996, 93(3):407-411.
210. Yao J.A., Du X., Lu D., Baker R.L., Daharsh E., Atterson P. J. Pharmacol. Toxicol. Methods 2005, 52(1):146-153.
211. Yap Y.G., Camm J. Br. Med. J. 2000, 320(7243):1158-1159.
212. Yap Y.G., Camm J. Quinolone Antimicrobial Agents 2008, 421-440. ASM Press, Washington, DC. 3rd ed. D.C. Hooper, E. Rubenstein (Eds.).
213. Zeltser D., Justo D., Halkin A., Prokhorov V., Heller K., Viskin S. Medicine 2003, 82(4):282-290.
214. Zhang M., Korolkova Y.V., Liu J., Jiang M., Grishin E.V., Tseng G.N. Biophys. J. 2003, 84(5):3022-3036.
215. Zheng W., Spencer R.H., Kiss L. Assay Drug Dev. Technol. 2004, 2(5):543-552.
216. Zon L.I., Peterson R.T. Nat. Rev. Drug Discov. 2005, 4(1):35-44.